Pulmonary embolism (PE) is a major cause of morbidity and mortality world-wide, and the
use of thrombolytic therapy has been associated with favourable clinical outcomes in certain …

Study objectives To determine the risk factors and frequency of intracranial hemorrhage
among patients undergoing thrombolysis for pulmonary embolism. Design A retrospective …

BACKGROUND: Intracranial hemorrhage is one of the dreaded complications of
thrombolytic therapy for acute pulmonary embolism. We identified patients with pulmonary …

Importance Thrombolytic therapy may be beneficial in the treatment of some patients with
pulmonary embolism. To date, no analysis has had adequate statistical power to determine …

Background Administration of systemic thrombolysis in pulmonary embolism (PE) has been
limited to severe forms due to the risk of intracerebral hemorrhage (ICH). There is growing …

Background Improved prediction of the risk of major bleeding in patients with acute
pulmonary embolism (PE) receiving systemic thrombolysis is crucial to guide the choice of …

Acute pulmonary embolism represents a major complication of venous thromboembolism
that is associated with high morbidity and mortality. Guidelines recommend the rapid …

While systemic intravenous thrombolysis decreases mortality in patients with high-risk
pulmonary embolism (PE), it clearly increases haemorrhagic risk. There are many …

Patients with pulmonary embolism can be divided in two groups according to their risk of
death or major complication: a small group of high‐risk patients defined by the presence of …

Background The use of thrombolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. To compare with anticoagulation alone, no analysis before has …